1. Introduction {#sec1-pharmaceutics-10-00221}
===============

Cancer has a major impact on global health as it is the second leading cause of death. According to the World Cancer Report 2014, the number of new cancer cases is expected to rise by about 70% over the next two decades \[[@B1-pharmaceutics-10-00221]\]. This is due to the rapidly ageing population, unhealthy lifestyles, and environmental pollutants, which could consist of carcinogens that can be present in the air, water, and soil, as well as in food as additives or contaminants. Early diagnosis of cancer allows timely treatment of the disease. Unfortunately, the early detection of cancer is still in its infancy as the progress in developing improved early diagnostics and screening tests has been inadequate. For instance, close to 70% of patients with lung cancer present with locally advanced or metastatic disease at the time of diagnosis. Therefore, surgical resection, the single most consistent and successful option for cure, cannot be performed \[[@B2-pharmaceutics-10-00221]\]. This thereby makes chemotherapy an important treatment option against cancer. Anticancer drugs are characterized by a narrow therapeutic window. Hence, it is important to understand and manage the inter-individual variability of drug exposure through genotyping/phenotyping and therapeutic drug monitoring (TDM) of anticancer drugs in the clinical setting. In the pharmaceutical industry, the current challenges in the development of anticancer drugs include the significant time and cost required for the preclinical and clinical testing of the new chemical entities (NCEs), and the low success rates. To overcome these obstacles, the pharmaceutical industry has been increasing its effort to improve the efficiency in the processes of drug discovery and development. This is in line with the objective of reducing the attrition rate of NCEs at later stages of the anticancer drug development pipeline, especially in clinical trials as by that stage a large portion of the cost of developing an oncology drug would have been incurred. According to a review article, two major underlying reasons accounting for drug attrition were identified \[[@B3-pharmaceutics-10-00221]\]. The first one is due to poor efficacy, which can be overcome by developing more predictive animal models in the preclinical phase. The second crucial factor is owing to poor pharmacokinetics (PK). To overcome the latter hurdle, a high throughput preclinical screening PK approach should be developed and validated. However, the success of PK analysis is highly dependent on the availability of rapid and sensitive bioanalytical assays for quantification of drugs in biological samples. Therefore, rapid and sensitive quantification of anticancer drugs in various biological matrices is urgently needed to discover novel and effective chemotherapeutic agents against various cancers. Liquid chromatography-tandem mass spectrometry (LC-MS/MS) offers superior specificity and sensitivity for compounds without natural chromophores or fluorophores. Hence, this highly sensitive and specific platform has been widely applied in investigating pharmacokinetic properties of novel anticancer drugs in their R&D in preclinical studies as well as in clinical trials. The workflow of LC-MS/MS proposed for bioanalytical method development is shown in [Figure 1](#pharmaceutics-10-00221-f001){ref-type="fig"}. The success for developing rapid and sensitive analytical methods is dependent on appropriate sample preparation, fast chromatographic separation to achieve symmetrical peaks, and efficient ionization.

The purpose of this review is to summarize the rapid LC-MS/MS methods for quantification of oncology drugs or potential anticancer compounds published in PubMed and Web of Science databases. In addition, important considerations regarding several crucial aspects in developing rapid LC-MS/MS methods, such as sample preparation, chromatographic separation, matrix effect evaluation, and internal standard selection will be discussed.

2. Method of Literature Search {#sec2-pharmaceutics-10-00221}
==============================

The literature search was conducted using the PubMed and Web of Science databases subscribed to by the National University of Singapore. The title phrase "rapid" or "fast" AND title or abstract phrase "LC-MS/MS" AND title or abstract phrase "cancer" were searched. The articles were then screened for their relevance to rapid quantification of anticancer drugs by LC-MS/MS. No date limitations were applied, and all articles retrieved were dated up to 30 May 2018. Additional relevant literature that was cited in the retrieved articles has also been reviewed. The scope of the review is limited to English language articles only.

3. Results and Discussion {#sec3-pharmaceutics-10-00221}
=========================

Based on the search method described, 72 papers have been found to be relevant to rapid quantification of anticancer drugs using LC-MS/MS methods. All of them have been classified into two categories based on the number of analytes. Forty-nine publications involved analyzing one drug (n = 1) and the remaining 23 involved analyzing multiple drugs/metabolites (n ≥ 2) are summarized in [Table 1](#pharmaceutics-10-00221-t001){ref-type="table"} \[[@B4-pharmaceutics-10-00221],[@B5-pharmaceutics-10-00221],[@B6-pharmaceutics-10-00221],[@B7-pharmaceutics-10-00221],[@B8-pharmaceutics-10-00221],[@B9-pharmaceutics-10-00221],[@B10-pharmaceutics-10-00221],[@B11-pharmaceutics-10-00221],[@B12-pharmaceutics-10-00221],[@B13-pharmaceutics-10-00221],[@B14-pharmaceutics-10-00221],[@B15-pharmaceutics-10-00221],[@B16-pharmaceutics-10-00221],[@B17-pharmaceutics-10-00221],[@B18-pharmaceutics-10-00221],[@B19-pharmaceutics-10-00221],[@B20-pharmaceutics-10-00221],[@B21-pharmaceutics-10-00221],[@B22-pharmaceutics-10-00221],[@B23-pharmaceutics-10-00221],[@B24-pharmaceutics-10-00221],[@B25-pharmaceutics-10-00221],[@B26-pharmaceutics-10-00221],[@B27-pharmaceutics-10-00221],[@B28-pharmaceutics-10-00221],[@B29-pharmaceutics-10-00221],[@B30-pharmaceutics-10-00221],[@B31-pharmaceutics-10-00221],[@B32-pharmaceutics-10-00221],[@B33-pharmaceutics-10-00221],[@B34-pharmaceutics-10-00221],[@B35-pharmaceutics-10-00221],[@B36-pharmaceutics-10-00221],[@B37-pharmaceutics-10-00221],[@B38-pharmaceutics-10-00221],[@B39-pharmaceutics-10-00221],[@B40-pharmaceutics-10-00221],[@B41-pharmaceutics-10-00221],[@B42-pharmaceutics-10-00221],[@B43-pharmaceutics-10-00221],[@B44-pharmaceutics-10-00221],[@B45-pharmaceutics-10-00221],[@B46-pharmaceutics-10-00221],[@B47-pharmaceutics-10-00221],[@B48-pharmaceutics-10-00221],[@B49-pharmaceutics-10-00221],[@B50-pharmaceutics-10-00221],[@B51-pharmaceutics-10-00221],[@B52-pharmaceutics-10-00221]\] and [Table 2](#pharmaceutics-10-00221-t002){ref-type="table"} \[[@B53-pharmaceutics-10-00221],[@B54-pharmaceutics-10-00221],[@B55-pharmaceutics-10-00221],[@B56-pharmaceutics-10-00221],[@B57-pharmaceutics-10-00221],[@B58-pharmaceutics-10-00221],[@B59-pharmaceutics-10-00221],[@B60-pharmaceutics-10-00221],[@B61-pharmaceutics-10-00221],[@B62-pharmaceutics-10-00221],[@B63-pharmaceutics-10-00221],[@B64-pharmaceutics-10-00221],[@B65-pharmaceutics-10-00221],[@B66-pharmaceutics-10-00221],[@B67-pharmaceutics-10-00221],[@B68-pharmaceutics-10-00221],[@B69-pharmaceutics-10-00221],[@B70-pharmaceutics-10-00221],[@B71-pharmaceutics-10-00221],[@B72-pharmaceutics-10-00221],[@B73-pharmaceutics-10-00221],[@B74-pharmaceutics-10-00221],[@B75-pharmaceutics-10-00221]\], respectively.

Currently, the unpreceded selectivity and continuously increasing sensitivity of LC-MS/MS have made it a particularly powerful and well established analytical technique to achieve rapid quantitation of anticancer drugs/metabolites in a very small volume of biological samples without tedious chromatographic separation and complicated sample preparation before mass signal detection. Some considerations in developing a LC-MS/MS for rapid quantitation of anticancer drugs will be further elaborated as follows.

3.1. Sample Preparation {#sec3dot1-pharmaceutics-10-00221}
-----------------------

Efficient sample preparation to avoid severe signal suppression due to the matrix effect is the first key step in achieving high sensitivity and specificity of rapid LC-MS/MS methods. Through sample preparation, we aim to isolate the target drugs/metabolites from the various biological matrices which contain a variety of endogenous components such as proteins, carbohydrates, salts, and lipids, etc. In general, there are three sample preparation methods for purifying the biological samples before injection into the MS/MS analyzer for quantitation of the target analyte(s). These sample preparation procedures can be accomplished through solid-phase extraction (SPE), liquid-liquid extraction (LLE), or protein precipitation (PPT). The results of all the 72 papers reviewed here suggested that PPT accounted for half of them (50%), followed by LLE (32.4%), and then SPE (17.6%), as shown in [Figure 2](#pharmaceutics-10-00221-f002){ref-type="fig"}.

SPE makes use of the affinity of solutes dissolved or suspended in a liquid (known as the mobile phase) to a solid matrix when the sample solution or suspension is passed through a cartridge packed with solid matrix, known as the stationary phase. During the process, the undesired endogenous components as well as the exogenous interfering compounds generated during the sample preparation process (e.g., plasticizers released from plastic tubes) have less affinity for the stationary phase. They readily pass through the cartridge leaving the analytes behind in the cartridge. After that, the analytes can be washed out from the cartridge using a different solvent in which the analytes have higher solubility. This process can remove interfering compounds efficiently through optimizing the types of cartridges and solvents used. In addition, it also allows for the enrichment of analytes when very low levels of drugs/metabolites are available to be quantified (e.g., in the situation involving microdosing of anticancer drugs in clinical trials). However, SPE is a labor-intensive process due to its complex procedure including column conditioning, sample loading, washing, and eluting, followed by evaporation of the eluent. This might account for only 18.1% of 72 papers in which the SPE was adopted. In addition, SPE cartridges are more expensive than the small volume of solvent used in LLE and PPT. Furthermore, PPT and LLE are more commonly used in quantification of single drugs/compounds. Only 12.2% of papers cited in [Table 1](#pharmaceutics-10-00221-t001){ref-type="table"} used SPE for sample preparation, but the usage of LLE is 40.8%, which is 2-fold higher than that of SPE. However, SPE was more popularly used in simultaneous quantification of multiple analytes/metabolites than LLE. Based on [Table 2](#pharmaceutics-10-00221-t002){ref-type="table"}, the percentage of SPE was greatly increased to 30.4% with a substantial decline of LLE usage to 13.0%. Nevertheless, application of SPE cartridges is limited when the drug of interest and its metabolites have very different solubility.

LLE is commonly used in the chemistry laboratory and the pharmaceutical industry to separate compounds based on their relative solubility in two different immiscible liquids, which are usually aqueous or biofluid samples, and an organic solvent such as hexane or ethers. It encompasses an extraction of a substance from one liquid into another liquid phase. LLE is especially suited to lipophilic compounds since the analytes transfer readily from the usually aqueous matrix to an organic phase. This procedure is followed by evaporation of the organic phase with OFN (oxygen-free nitrogen). Comparatively, LLE is much simpler and relatively inexpensive compared to SPE. However, it is not suitable for hydrophilic drugs/metabolites, unless derivatization is done (which is commonly used for GC-MS). Hence, LLE is usually used for determination of a single analyte but not suitable for simultaneous quantification of multiple drugs which have significantly different lipophilicity, resulting in large and different recoveries among the analytes.

PPT is the simplest method of sample pre-treatment as it involves only the addition of a precipitating solvent, subsequent vortex, and centrifugation. The more frequently used solvents for PPT include acetonitrile and methanol. The resulting supernatant is then injected into the LC-MS/MS system for analysis. The advantage of PPT is simple, rapid, and inexpensive. In addition, it is suitable for both lipophilic and hydrophilic analytes. This is a very unique feature as compared to SPE and LLE that cannot extract hydrophilic compounds. This unique property of PPT is very important for quantitative analysis of the relatively hydrophilic drugs or for simultaneous determination of lipophilic drugs with both their lipophilic and hydrophilic metabolites (e.g., exemestane and its phase I and phase II metabolites, 17β-2H-exemestane and 17β-2H-exemestane-*O*-glucuronide) \[[@B68-pharmaceutics-10-00221]\]. PPT, however, does not always produce very clean extracts, as many matrix constituents can be extracted simultaneously with the analyte. That can interfere with the MS/MS detection. The interference can be particularly serious when the volume of the biological sample is large (\>50 µL).

In summary, there was a significant difference in application of these three methods. The number of studies using PPT alone was equivalent to the combined number of studies using LLE and SPE. In addition, the percentage of LLE at 31.9% was much greater than that of SPE at 18.1%. Based on [Table 2](#pharmaceutics-10-00221-t002){ref-type="table"}, SPE played an important role for simultaneous quantification of multiple drugs/compounds. Only PPT can be used as the sample preparation procedure for the simultaneous quantitation of parent drugs and their hydrophilic metabolites. Taken together, PPT is the most widely used method for preparation of biological samples. The major reason is that most of the metabolites are much more hydrophilic than their parent drugs, particularly for Phase II metabolites which are not able to be extracted with LLE and SPE. However, PPT can extract both a parent drug and its metabolites at an equally high recovery. Therefore, PPT becomes the first choice for sample preparation due to the extremely high selectivity of the MS/MS analyzer and its increasingly improved sensitivity, making quantification of analytes in a small micro volume of biological samples (≤10 µL) possible.

3.2. Chromatographic Separation {#sec3dot2-pharmaceutics-10-00221}
-------------------------------

Chromatography is undoubtedly the most important analytical method for identification and quantitation of a drug and its metabolites since 1952, when Archer J.P. Martin and Richard L.M. Synge were jointly awarded the Nobel Prize in Chemistry for their proposed concept of partition chromatography. Based on the concept, various chromatographic techniques and columns have been developed to separate chemicals with only slight differences in partition coefficients between the mobile and stationary phases. Since the second half of the 20th century, liquid chromatography has been widely used in analysis in the pharmaceutical industry for bioanalysis of drugs in preclinical studies and clinical trials. A lot of analytical methods have been published on the determination of various drugs with liquid chromatography coupled with a UV detector. However, this analytical process used for quantification of analytes in biological samples is quite tedious and time consuming due to the poor selectivity of UV detection---a widely used analytical approach for pharmaceutical analysis in the last century. For analysis using liquid chromatography with UV detection, sample preparation is usually very challenging for analytical scientists as endogenous compounds and co-administered drugs have to be removed via sample preparation as much as possible to minimize the background interference in the analysis. The chromatographic run time is usually long, ranging from 30 to 60 min. This is because the target drugs/metabolites have to be chromatographically separated from both endogenous and exogenous interfering compounds prior to detection and measurement. In the mid last century, a revolutionary change in pharmaceutical analysis was made when the LC-MS/MS was invented. In contrast to most LC-UV analytical methods, LC-MS/MS is able to discern the analyte(s) from the matrix components with the presence of other endogenous substances and spiked internal standards, even if they are co-eluted due to the superior selectivity of MS/MS. However, the potential problem of harmful ion suppression or enhancement from the co-eluting peaks still has to be overcome in the process of developing and validating the LC-MS/MS methods for rapid determination of anticancer drugs/metabolites. This will be further elaborated in the later part of this review.

The extremely high selectivity and continuously increasing sensitivity of MS/MS lays the foundation for achieving a rapid quantification of analytes in various biological matrices. The run time (RT)---the total time necessary for completing a chromatographic separation---reported in the 72 papers, has been summarized in [Table 1](#pharmaceutics-10-00221-t001){ref-type="table"} and [Table 2](#pharmaceutics-10-00221-t002){ref-type="table"}. Their distribution was shown in [Figure 3](#pharmaceutics-10-00221-f003){ref-type="fig"} and [Figure 4](#pharmaceutics-10-00221-f004){ref-type="fig"}, respectively. Based on [Figure 3](#pharmaceutics-10-00221-f003){ref-type="fig"}, the two top percentages of the fastest run times are 36% and 28% (both are shaded) for RT 1.5 → 3.0 min and 3.1 → 4.0, respectively, for the determination of 1 analyte. The combined percentage with these 2 RTs is equal to 64%. Hence, it is reasonable to define a run time of ≤4 min as rapid quantification of one drug in biological matrices. On the other hand, a run time of ≤6 min could be defined as rapid quantification of ≥2 analytes based on [Figure 4](#pharmaceutics-10-00221-f004){ref-type="fig"} in which two top percentages of the fastest run times are 39% and 38% (both are shaded) for RT 4.1 → 5.0 min and 5.1 → 6.0, respectively. This is because as many as 92% of the papers listed in [Table 2](#pharmaceutics-10-00221-t002){ref-type="table"} reported a RT of ≤6 min for the chromatographic separation of analytes or above. Taken together, the run time to achieve rapid analysis for 1 drug and ≥2 drugs/metabolites are 4 and 6 min, respectively.

The longer run time for determination of ≥2 drugs/metabolites can be explained by the frequent use of gradient elution mode in order to achieve good separation of drugs from the other drugs or their own metabolites. Based on [Table 2](#pharmaceutics-10-00221-t002){ref-type="table"}, as many as 78.3% of the methods for the determination of ≥2 drugs/metabolites adopted gradient elution mode but only 40.8% of the methods for the determination of one drug adopted this elution mode. In general, gradient elution typically takes a longer time in the elution of compounds as the column has to be re-equilibrated back to the starting gradient conditions before reliable retention can be achieved in the subsequent runs. However, the issue on longer run time of gradient elution mode can be circumvented by the use of an ultra-high performance liquid chromatography (UPLC) system. In UPLC, sub-2 µm particles are used in contrast to the standard particle sizes of 3--5 µm used in conventional HPLC columns, resulting in a faster chromatographic analysis \[[@B76-pharmaceutics-10-00221]\]. This results in a shorter time for the mobile phase to be re-equilibrated. UPLC coupled with gradient elution works well in determination of multiple analytes. That accounts for 36.6% of all studies, as shown in [Table 2](#pharmaceutics-10-00221-t002){ref-type="table"}. In contrast, gradient elution for UPLC is only used in 6.1% of all studies for analyzing one analyte, as shown in [Table 1](#pharmaceutics-10-00221-t001){ref-type="table"}. For instance, Bouchet et al. reported a well-validated UPLC-MS/MS method for simultaneous determination of nine tyrosine kinase inhibitors within 4 min of run time only \[[@B56-pharmaceutics-10-00221]\]. Similarly, Merienne et al. achieved high throughput routine determination of 17 tyrosine kinase inhibitors by another UPLC-MS/MS method \[[@B58-pharmaceutics-10-00221]\]. In addition, UPLC separation with gradient mode also improves the peak shapes of the later-eluting compounds and gives chromatographic bands that are more evenly spaced \[[@B77-pharmaceutics-10-00221]\].

Contrary to HPLC-UV methods, a baseline chromatographic separation is not needed in LC-MS/MS analysis to elute the target analytes from other interfering compounds during method development, especially for determination of one drug while its metabolites present different mass transitions. However, when a drug and its metabolites are determined simultaneously, the separation between a parent drug and its metabolites is usually necessary as the metabolites, particularly its phase II conjugated metabolites, may have similar fragmentation profiles as the parent drug, leading to inaccurate measurement of the analyte \[[@B78-pharmaceutics-10-00221]\].

With reference to the papers listed in [Table 2](#pharmaceutics-10-00221-t002){ref-type="table"}, some authors only indicated the stationary phase and mobile phase conditions used without discussion in detail of the optimization of the chromatographic separation, while the rest reported a multi-factorial optimization on LC column selection (C8 or C18), mobile phase components, and ratios, as well as the flow rates of the mobile phase. Generally, all these optimizations were empirical and not much theoretical explanation was given. Nevertheless, a research group in the US proposed a theory-guided efficient strategy to maximize the speed and resolution in rapid gradient LC-MS/MS analysis \[[@B79-pharmaceutics-10-00221]\]. They systematically studied the effect of gradient time, initial and final eluent strength (% organic), and flow rate on the separation resolution and peak capacity in a gradient elution of a mixture of five structurally-related compounds. It was also demonstrated experimentally that increasing flow rate improves both resolution and peak capacity in a rapid gradient method. The results can be well explained mathematically using the linear-solvent-strength (LSS) gradient theory. This further supports our finding that UPLC-coupled gradient elution is an efficient approach for simultaneous quantification of multiple analytes in a short run time (≤6 min). In regard to internal standards, as many as 74.3 of the internal standards from 72 papers are structural analogues even though stable isotopically labelled (SIL) analogues of the analytes are preferred in achieving better quantitative results. The main reasons are (1) not commercially available or (2) too expensive.

3.3. Matrix Effects {#sec3dot3-pharmaceutics-10-00221}
-------------------

Although MS/MS has been demonstrated to possess superior selectivity and sensitivity, the signal is often affected significantly by the biological matrix residues. Ion suppression or enhancement remains an inherent problem in LC-MS/MS method development and could be the result of interference of endogenous substances from the biological matrices (e.g., human plasma) or exogenous substances during sample preparation (e.g., polymers from polypropylenetubes) \[[@B80-pharmaceutics-10-00221]\]. The alteration of ionization efficiency by the presence of co-eluting substances is called "matrix effects". These effects are not detectable in the chromatogram but have deleterious impacts on the method's accuracy and sensitivity. Hence, an assessment of matrix effects is needed according to the European Medicine Agency (EMA) and USA Food and Drug Administration (FDA) guidelines so as to ensure that precision, selectivity, and sensitivity of LC-MS/MS analyses are not compromised \[[@B81-pharmaceutics-10-00221]\]. A series of experiments were conducted to explore the mechanism of matrix effects and the authors concluded that the possible reason was due to the result of competition between non-volatile matrix components and analyte ions for access to the droplet surface for transfer to the gas phase \[[@B82-pharmaceutics-10-00221]\]. Therefore, application of suitable methods for the evaluation of matrix effects plays an important role in developing and validating a sensitive and robust analytical method for the determination of anticancer drugs/metabolites in biological matrices.

Generally, there are two common methods to assess matrix effects. One is the post-extraction addition method, while the other is the post-column infusion method. In 2003, Matuszewski et al. published a research paper discussing the strategies for the assessment of the matrix effect in quantitative bioanalytical methods based on LC-MS/MS \[[@B80-pharmaceutics-10-00221]\]. The matrix effect during validation of analytical methods in biological fluids may be best examined by comparing the MS/MS response (peak areas or peak heights) of an analyte at any given concentration spiked post-extraction into a biological fluid extract (B), to the MS/MS response (A) of the same analyte present in the "neat" mobile phase. The equation of matrix effect (%) can be expressed as follows:

A value of 100% indicates that the responses in the "neat" mobile phase and the plasma extracts were the same and no absolute matrix effect was observed. A value of \>100% indicates an ionization enhancement and a value of \<100% indicates an ionization suppression. The post-extraction addition technique is a quantitative but static approach that only provides information about matrix effects at the point of elution of the analyte. A more dynamic technique for determining matrix effects is the post-column infusion method \[[@B82-pharmaceutics-10-00221]\]. The post-column infusion system is schematically represented in [Figure 5](#pharmaceutics-10-00221-f005){ref-type="fig"}. An infusion pump was used to deliver a constant flow of analyte at a concentration in the range of quantitation into the chromatographic eluent at a point after the column and before the mass spectrometer ionization source \[[@B83-pharmaceutics-10-00221]\]. A sample of extract (without added analyte) was injected under the desired chromatographic conditions and the response from the infused analyte recorded. The post-infusion technique enables the influence of the matrix on analyte response to be investigated over the entire chromatographic run. Nevertheless, the post-infusion approach is a qualitative or semi-quantitative method. It can be used to evaluate the influence of different sample extraction methods, chromatographic conditions such as mobile phase components, and analytical columns on matrix effects.

Due to the critical influence of matrix effects on mass analyzers, matrix effects have to be evaluated systematically during the development of well-validated and rapid LC-MS/MS methods. Among the 72 papers of rapid analytical LC-MS/MS methods for determination of anticancer drugs and their metabolites in [Table 1](#pharmaceutics-10-00221-t001){ref-type="table"} and [Table 2](#pharmaceutics-10-00221-t002){ref-type="table"}, 11 papers did not mention matrix effects. Two of them were published in 2003 when the impact of matrix effects on the LC-MS/MS methods had not been fully recognized by analytical scientists. Nevertheless, the majority of the studies incorporated in our review (61 out of 72, 84.7%) have reported matrix effects of the analytes in various biological samples during method development and validation. In addition, the matrix effects in all of these 61 papers were evaluated using the post-extraction addition approach. The reasonable explanation is that the post-extraction addition technique is a quantitative approach for the evaluation of matrix effects on the analytes. Based on the quantitative analysis of matrix effects, effective solutions to overcome potential matrix effects or at least minimize the influence of matrix effects on sensitivity and accuracy of the LC-MS/MS methods are needed during method development.

The matrix effect is a common phenomenon in the quantitation of drugs and metabolites in biological matrices using LC-MS/MS. Since the matrix effect could be potentially caused by the influence of co-eluting non-volatile matrix components on the ionization efficiency of the analytes, it can be minimized, avoided, or compensated mainly through optimization of sample preparation, chromatographic separation, and suitable internal standard, respectively. In theory, SPE is an ideal sample preparation assay in which matrix effects can be eliminated efficiently because the analytes can be efficiently isolated from the matrix via suitable SPE columns and elution solutions. However, it is a very tedious and time-consuming process. Comparatively, LLE is a simpler and faster procedure for the preparation of biological samples but the purified samples may still contain some lipophilic endogenous compounds which could potentially affect the quantification of analytes. In such a case, chromatographic separation can be optimized to minimize the resulting matrix effects due to inherent limitation of LLE. As a widely used bio-sample preparation assay, PPT is the most convenient approach, but the purified samples may also be much dirtier than the samples extracted by the SPE or LLE techniques. However, an important fact to note is that increasingly improved sensitivity of LC-MS/MS provides us a good chance to use a minute volume of biological samples, e.g., 5 µL of plasma or serum for analysis. In this scenario, the residue of impurities derived from PPT is negligible in most cases. This is the reason why PPT was adopted as the sample preparation for rapid determination of anticancer drugs/metabolites using a LC-MS/MS platform in the majority of the 72 papers reviewed.

4. Conclusions and Perspectives {#sec4-pharmaceutics-10-00221}
===============================

Rapid liquid chromatography-tandem mass spectrometry plays an important role in both preclinical development and clinical trials. Based on the papers published in English, the assay run times of rapid LC-MS/MS methods for a single analyte and multiple analytes were identified as 4 and 6 min, respectively. With the development of UPLC systems and the availability of more isotopically-labelled internal standards, assay run times for rapid analysis of anticancer drugs/metabolites could be further reduced in order to accelerate drug development.

In the preparation of biological samples, PPT is widely applied as it is the simplest sample preparation approach and can be used to quantify both hydrophilic and lipophilic compounds simultaneously, thereby making it the most popular method compared to SPE and LLE. Structural analogues are mostly used as internal standards, given the consideration of costs and availability. In the future, great effort should be made to establish the principles in selection of appropriate internal standards, which are chosen mainly based on a trial and error approach.

Currently, LC-MS/MS has been widely used to investigate pharmacokinetics of oncology drugs to support early phase clinical trials and determine potential drug--drug interactions. The advantage in using LC-MS/MS is its super sensitivity and specificity, which makes it a powerful tool for clinical therapeutic monitoring of oncology drugs.
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pharmaceutics-10-00221-t001_Table 1

###### 

LC-MS/MS methods for determination of one drug.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Analyte(s)                Indication                        Matrices    Prep   Solid Phase                     E-M   Interf    IS   ME (%)         RT (min)   LLOQ                  Ref.
  ------------------------- --------------------------------- ----------- ------ ------------------------------- ----- --------- ---- -------------- ---------- --------------------- -----------------------------------
  Nimorazole                Radiosensitizer                   r-plasma    PPT    C18 (50 × 4.6 mm, 2.7 µm)       ISO   ESI(+)    AN   NEG            1.5        0.25 ng/mL            \[[@B4-pharmaceutics-10-00221]\]

  JI-101                    Multi-kinase inhibitor            h-plasma\   SPE    C18 (50 × 2.1 mm, 5 µm)         ISO   ESI(+)    AN   98             2.0        1.57 ng/mL\           \[[@B5-pharmaceutics-10-00221]\]
                                                              h-urine                                                                                           0.97 ng/mL            

  LBH589                    HDAC inhibitor                    m-plasma\   LLE    C18 (50 × 2.1 mm, 1.7 µm)\      ISO   ESI(+)    AN   NEG            2.0        2.5 ng/mL\            \[[@B6-pharmaceutics-10-00221]\]
                                                              m-tissue           UPLC                                                                           35.7 ng/mg            

  Vinorelbine               Vinca alkaloid                    h-plasma    LLE    C18 (50 × 2.1 mm, 3 µm)         ISO   ESI(+)    AN   95.8--106.7    2.0        0.1 ng/mL             \[[@B7-pharmaceutics-10-00221]\]

  Cerivastatin              Inhibitor of HMG-CoA reductase    h-plasma    LLE    C18 (100 × 3 mm, 3.5 µm)        ISO   ESI(+)    AN   NEG            2.0        0.01 ng/mL            \[[@B8-pharmaceutics-10-00221]\]

  Osimertinib               Tyrosine kinase inhibitor         r-plasma    PPT    C18 (50 × 2.1 mm, 3 µm)         GRA   ESI(+)    AN   90.1--97.3     2.5        1 ng/mL               \[[@B9-pharmaceutics-10-00221]\]

  Anastrazole               Aromatase inhibitor               h-plasma    SPE    C18 (50 × 4.6 mm, 5 μm)\        ISO   ESI(+)    AN   97.5           2.5        0.3 ng/mL             \[[@B10-pharmaceutics-10-00221]\]
                                                                                 UPLC                                                                                                 

  SZ-685C                   Marine anticancer agent           r-plasma    LLE    C18 (100 × 2.1 mm, 3 µm)        ISO   ESI(−)    AN   94.3           2.5        5 ng/mL               \[[@B11-pharmaceutics-10-00221]\]

  CLR1401                   Anticancer candidate              r-plasma    LLE    C18 (50 × 3.0 mm, 5 µm)         GRA   ESI(+)    IL   80.0--86.0     2.8        2 ng/mL               \[[@B12-pharmaceutics-10-00221]\]

  Veliparib (ABT-888)       PARP-1 & 2 inhibitor              h-plasma    PPT    C18 (100 × 2.1 mm, 3 µm)        ISO   ESI(+)    AN   UNK            3.0        5 nmol/L              \[[@B13-pharmaceutics-10-00221]\]

  Docetaxel                 Anticancer drug                   h-plasma    LLE    C8 (50 × 2.1 mm, 5 µm)          ISO   ESI(+)    AN   UNK            3.0        5 ng/mL               \[[@B14-pharmaceutics-10-00221]\]

  Aucubin                   Natural compound                  r-plasma    PPT    Diamonsil C18(2)                ISO   ESI(+)    AN   90.8--91.0     3.0        10 ng/mL              \[[@B15-pharmaceutics-10-00221]\]

  HCQ                       Inhibitor of autophagy            h-blood     PPT    C8 (50 × 2.1 mm, 5 µm)          ISO   ESI(+)    IL   93.0--100.6    3.0        5 ng/mL               \[[@B16-pharmaceutics-10-00221]\]

  Sunitinib                 Tyrosine kinase inhibitor         h-plasma    LLE    C18 (50 × 2.1 mm, 3.5 µm)       ISO   ESI(+)    AN   UNK            3.0        0.2 ng/mL             \[[@B17-pharmaceutics-10-00221]\]

  DZNep                     Methylation inhibitor             m-plasma    LLE    HILIC (100 × 2.1 mm, 1.7 µm)\   GRA   ESI(+)    AN   84--87         3.0        5 ng/mL               \[[@B18-pharmaceutics-10-00221]\]
                                                                                 UPLC                                                                                                 

  SN-38                     Anticancer drug                   h-plasma    PPT    C18 (50 × 2.0 mm, 4 µm)         GRA   ESI(+)    AN   UNK            3.0        0.05 ng/mL            \[[@B19-pharmaceutics-10-00221]\]

  Vincristine               Anticancer drug                   h-plasma    PPT    C18 (50 × 2.1 mm, 5 µm)         ISO   APCI(+)   AN   UNK            3.0        0.1 ng/mL             \[[@B20-pharmaceutics-10-00221]\]

  MS-275                    HDAC inhibitor                    h-plasma    LLE    C18(50 × 2.1 mm, 3.5 μm)        GRA   ESI(+)    AN   UNK            3.0        0.5 ng/mL             \[[@B21-pharmaceutics-10-00221]\]

  trans-resveratrol         Natural compound                  m-plasma\   LLE    C18 (100 × 1 mm, 5 μm)          ISO   ESI(−)    AN   93.8--100.6    3.0        5 ng/mL               \[[@B22-pharmaceutics-10-00221]\]
                                                              m-brain                                                                                                                 

  ZD6474                    Tyrosine kinase inhibitor         h-plasma\   LLE    C18 (50 × 2.1 mm, 2.6 µm)       ISO   ESI(+)    IL   98.0           3.0        0.25 ng/mL\           \[[@B23-pharmaceutics-10-00221]\]
                                                              h-fluid                                                                                           0.25 ng/mL            

  Crizotinib                Tyrosine kinase inhibitor         r-plasma    PPT    Zorbax XDB C18\                 GRA   ESI(+)    AN   94.3--96.2     3.5        1 ng/mL               \[[@B24-pharmaceutics-10-00221]\]
                                                                                 (2.1 × 50 mm, 3.5 μm)                                                                                

  cabozantinib              Tyrosine kinase inhibitor         r-plasma    LLE    C18 (50 × 2 mm, 5 μm)           ISO   ESI(+)    AN   105--115       3.5        0.5 ng/mL             \[[@B25-pharmaceutics-10-00221]\]

  KPS-A                     Natural compound                  r-plasma    PPT    C18 (2.1 × 50 mm, 3.5 μm)       GRA   ESI(+)    AN   93--96         3.5        0.5 ng/mL             \[[@B26-pharmaceutics-10-00221]\]

  Clofarabine\              Metabolite of clofarabine         h-PBMC      PPT    CN (100 × 4.6 mm, 5 μm)         GRA   ESI(+)    AN   91--105        3.5        1.25 ng/10^7^ cells   \[[@B27-pharmaceutics-10-00221]\]
  triphosphate                                                                                                                                                                        

  Paclitaxel                Antimicrotubule agent             r-plasma\   LLE    C8 (50 × 2.1 mm, 5 μm)          ISO   ESI(+)    IL   70.9--82.7     3.5        0.5 ng/mL\            \[[@B28-pharmaceutics-10-00221]\]
                                                              r-tissue                                                                                          1.5 ng/g              

  EDL-155                   Anticancer agent                  r-plasma    PPT    C8 (50 × 2.1 mm, 3.5 μm)        GRA   ESI(+)    AN   98.6           3.5        0.1 ng/mL             \[[@B29-pharmaceutics-10-00221]\]

  Henatinib                 Kinase inhibitor                  h-plasma\   PPT    C18 (50 × 2.1 mm, 2.5 μm)       ISO   ESI(+)    AN   90.5--100.9    3.5        0.1 ng/mL\            \[[@B30-pharmaceutics-10-00221]\]
                                                              h-urine                                                                                           1 ng/mL               

  Ceritinib                 ALK inhibitor                     h-plasma\   PPT    C18 (50 × 2.1 mm, 2.7 μm)       GRA   ESI(+)    IL   92--109        3.6        1 ng/mL               \[[@B31-pharmaceutics-10-00221]\]
                                                              h-brain                                                                                                                 

  Methergine                chemosensitizer for cancer        h-plasma    LLE    C18 (100 × 2.1 mm, 2.7 μm)      ISO   ESI(+)    AN   61--66         4.0        0.025 ng/mL           \[[@B32-pharmaceutics-10-00221]\]

  Letrozole                 Aromatase inhibitor               h-plasma    SPE    C18 (100 × 2.1 mm, 3.5 μm)      ISO   ESI(+)    AN   NEG            4.0        0.25 ng/mL            \[[@B33-pharmaceutics-10-00221]\]

  Deacetyl mycoepoxydiene   Marine anticancer agent           r-plasma    PPT    C18 (150 × 2.1 mm, 5 μm)        ISO   ESI(+)    AN   95.5--97.8     4.0        5 ng/mL               \[[@B34-pharmaceutics-10-00221]\]

  Sorafenib                 Kinase inhibitor                  h-plasma    PPT    SymmetryShield RP8\             ISO   ESI(+)    IL   98.6           4.0        5 ng/mL               \[[@B35-pharmaceutics-10-00221]\]
                                                                                 (50 × 2.1 mm, 3.5 μm)\                                                                               
                                                                                 (0.1% FA:ACN)                                                                                        

  QBH-196                   c-Met tyrosine kinase inhibitor   r-plasma    LLE    C18 (50 × 2.1 mm, 2.6 µm)       GRA   ESI(+)    AN   80--115        4.0        8 ng/mL               \[[@B36-pharmaceutics-10-00221]\]

  Fenretinide               Chemopreventive agent             m-plasma    PPT    C18 (50 × 2.1 mm, 5 μm)         GRA   APCI(+)   AN   100.8--108.7   4.5        0.5 ng/mL             \[[@B37-pharmaceutics-10-00221]\]

  PM01183                   Antineoplastic agent              Animal\     SPE    C18 (30 × 2.1 mm, 3 μm)         GRA   ESI(+)    IL   88--103        5.0        0.1 ng/mL             \[[@B38-pharmaceutics-10-00221]\]
                                                              plasma                                                                                                                  

  JCC76                     Antitumor agent                   r-plasma    LLE    C18 (40 × 2.0 mm, 5 μm)         ISO   ESI(−)    AN   90.8--96.9     5.0        0.3 ng/mL             \[[@B39-pharmaceutics-10-00221]\]

  Megestrol acetate         Hormonal therapy                  h-plasma    LLE    C18 (50 × 2.0 mm, 3 µm)         ISO   ESI(+)    AN   92.3--95.8     5.0        1.0 ng/mL             \[[@B40-pharmaceutics-10-00221]\]

  Berbamine                 Natural compound                  r-plasma    PPT    C18 (150 × 2.0 mm, 5 μm)        GRA   ESI(+)    AN   97.2--98.5     5.5        1 ng/mL               \[[@B41-pharmaceutics-10-00221]\]

  Peri-plocymarin           potential anticancer agent        r-plasma\   LLE    C18 (2.1 × 150 mm, 3.0 μm)      ISO   ESI(+)    AN   95.8--105      6.0        0.5 ng/mL             \[[@B42-pharmaceutics-10-00221]\]
                                                              r-tissue                                                                                                                

  ABL                       potential anticancer agent        r-plasma    PPT    C18 (50 × 4.6 mm, 3.0 μm)       ISO   ESI(+)    AN   104--108       6.0        1.6 ng/mL             \[[@B43-pharmaceutics-10-00221]\]

  Cisplatin                 Anticancer drug                   r-tissue    LLE    C18 (50 × 2.1 mm, 1.8 μm)       ISO   ESI(+)    AN   89--104        6.0        5 ng/mL               \[[@B44-pharmaceutics-10-00221]\]

  EC-18                     Anticancer agent                  r-plasma\   PPT    C18 (150 × 2 mm, 4.0 μm)        GRA   ESI(+)    IL   77.9--89.0     7.0        50 ng/mL              \[[@B45-pharmaceutics-10-00221]\]
                                                              m-plasma                                                                                                                

  Z-endoxifen               Anti-estrogen                     h-serum     PPT    C18 (150 × 2.1 mm, 2.6 µm)      GRA   ESI(+)    IL   NA             7.0        1 ng/mL               \[[@B46-pharmaceutics-10-00221]\]

  5-azacytidine             Anticancer agent                  h-plasma    SPE    C18 (250 × 2.1 mm, 4 µm)        ISO   ESI(+)    AN   51--55         7.0        5 ng/mL               \[[@B47-pharmaceutics-10-00221]\]

  RGB-286638                Protein kinase inhibitor          h-plasma\   LLE    C18 (50 × 2.1 mm, 5 µm)         GRA   ESI(+)    IL   146--151       7.0        2 ng/mL\              \[[@B48-pharmaceutics-10-00221]\]
                                                              h-urine                                                                                           2 ng/mL               

  Azurin p28                Anticancer peptide                m-ser       PPT    C18 (100 × 2 mm, 5 µm)          GRA   ESI(+)    AN   UNK            7.5        100 ng/mL             \[[@B49-pharmaceutics-10-00221]\]

  Apogossypol               Bcl-2 inhibitor                   m-plasma    PPT    C18 (100 × 2 mm, 4 µm)          GRA   ESI(+)    AN   UNK            7.5        10 ng/mL              \[[@B50-pharmaceutics-10-00221]\]

  Methotrexate              Anticancer drug                   h-saliva    SPE    C18 (150 × 2.0 mm, 2.2 μm)      GRA   ESI(+)    AN   96--104        8.0        1.0 ng/mL             \[[@B51-pharmaceutics-10-00221]\]

  CSUOH0901                 COX-2 inhibitor                   r-plasma    PPT    C18 (50 × 2.0 mm, 5 μm)         GRA   ESI(+)    AN   90.1--94.5     8.0        0.5 ng/mL             \[[@B52-pharmaceutics-10-00221]\]
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: Prep: sample preparation; S-Ph (M-Ph): Solid phase (Mobile phase); E-M: Elution mode; Interf: Interface; IS: Internal standard; RT: Run time; LLOQ: Lower limit of quantitation; Ref.: Reference number; h: human; m: mouse; r: rat; d: dog; LLE: liquid-liquid extraction; SPE: solid phase extraction; PPT: protein precipitation; ISO: isocratic elution; GRA: gradient elution; AN: analogue internal standard; IL: isotope labeled internal standard; LBH589: Panobinostat; HCQ: Hydroxychloroquine; JCC76: Cyclohexanecarboxylic acid \[3-(2,5-dimethyl-benzyloxy)-4-(methanesulfonyl-methyl-amino)-phenyl\]-amide; DZNep: 3-Deazaneplanocin A; EDL-155: 1,2,3,4-tetrahydroisoquinoline; ZD6474: vandetanib; PR104: (A: alcohol; H: hydroxylamine; M: amine; G: O-glucuronide); CA4P: combretastatin A4 phosphate; CA4: combretastatin A4; CA4G: combretastatin A4 glucuronide; ABL:1-O-acetylbritannilactone; KPS-A: kalopanaxsaponin A; QBH-196: N1-(3-fluoro-4-{6-methoxy-7-\[3-(4-methylpiperidin-1-yl) propoxy\] quinolin-4-yloxy}phenyl)-N4-(2,4-difulurobenzylidene) semicarbazided; NA: not available; NEG: negligible matrix effect; UNK: unknown; ME: matrix effect; UPLC: Ultra-Performance Liquid Chromatography.
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###### 

LC-MS/MS methods for determination of two or more drugs/metabolites.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Analyte(s)                      Indication                                                       Matrices    Prep   S-Ph                             E-Mode   Interf    IS    ME (%)              RT (min)   LLOQ            Ref.
  ------------------------------- ---------------------------------------------------------------- ----------- ------ -------------------------------- -------- --------- ----- ------------------- ---------- --------------- -----------------------------------
  Belinostat\                     HDAC inhibitor                                                   r-plasma    PPT    C18 (50 × 4.6 mm, 5 μm)          ISO      ESI(+)    AN    No significant ME   2.5        2.9 ng/mL\      \[[@B53-pharmaceutics-10-00221]\]
  Panobinostat\                                                                                                                                                                                                2.9 ng/mL\      
  Rocilinostat\                                                                                                                                                                                                1.0 ng/mL\      
  Vorinostat                                                                                                                                                                                                   1.0 ng/mL       

  CT-707\                         Tyrosine kinase\                                                 h-plasma    SPE    C18 (2.1 × 50 mm, 1.7 μm)\       GRA      ESI(+)    IL    86.9--102           3.0        2 ng/mL\        \[[@B54-pharmaceutics-10-00221]\]
  CT-707M1\                       selective inhibitor                                                                 UPLC                                                                                     1 ng/mL\        
  CT-707M2                                                                                                                                                                                                     1 mg/mL         

  Gefitinib\                      EGFR inhibitor                                                   h-plasma    PPT    C18 (150 × 2.1 mm, 5 µm)         ISO      ESI(+)    AN    93.0--103.3;\       3.0        5 nmol/L        \[[@B55-pharmaceutics-10-00221]\]
  O-DMG                                                                                                                                                                         41.6--50.2                                     

  Sunitinib\                      Nine tyrosine kinase inhibitors and one metabolite of Imatinib   h-pls       SPE    C18 (50 × 2.1 mm, 1.7 μm)\       GRA      ESI(+)    IL    96.6\               4.0        10 ng/mL\       \[[@B56-pharmaceutics-10-00221]\]
  Gefitinib\                                                                                                          UPLC                                                      104.5\                         0.1 ng/mL\      
  Norimatinib (met)\                                                                                                                                                            85.5\                          10 mg/mL\       
  Imatinib\                                                                                                                                                                     85.0\                          10 ng/mL\       
  Dasatinib\                                                                                                                                                                    84.5\                          0.1 ng/mL\      
  Erlotinib\                                                                                                                                                                    81.6\                          10 mg/mL\       
  Axitinib\                                                                                                                                                                     113.1\                         0.1 ng/mL\      
  Nilotinib\                                                                                                                                                                    101.8\                         10 ng/mL\       
  Lapatinib\                                                                                                                                                                    91.2\                          10 mg/mL\       
  Sorafenib\                                                                                                                                                                    107.7                          0.1 mg/mL       

  MTX\                            Anticancer drug                                                  m-plasma\   PPT    C18 (50 × 2.0 mm, 5 µm)          ISO      ESI(+)    IL    88.2--108.8         4.0        3.7 ng/mL\      \[[@B57-pharmaceutics-10-00221]\]
  7-OH-MTX                                                                                         m-brain                                                                                                     7.4 ng/mL       

  17 tyrosine kinase inhibitors   EGFR tyrosine kinase inhibitors                                  h-plasma    SPE    C18 (5 × 2.1 mm, 1.6 µm)\        GRA      ESI(+)    IL    83.4--116.40        5.0        0.1 ng/mL       \[[@B58-pharmaceutics-10-00221]\]
                                                                                                                      UPLC                                                                                                     

  Doxorubicin\                    Anticancer antibiotic                                            h-plasma    SPE    C18 (50 × 2.1 mm, 5.0 μm)        GRA      ESI(+)    AN\   95.7--98.9          5.0        3.13 ng/mL\     \[[@B59-pharmaceutics-10-00221]\]
  L-DOX                                                                                                                                                                   IL                                   0.15 μg/mL      

  Vemurafenib,\                   2 BRAF inhibitors\                                               h-plasma    SPE    C18 (100 × 2.1 mm, 5.0 μm)\      GRA      ESI(+)    IL    80.6--115.4         5.0        0.4 ng/mL\      \[[@B60-pharmaceutics-10-00221]\]
  Dabrafenib\                     3 MEK inhibitors                                                                    UPLC                                                                                     1.0 ng/mL\      
  Cobimetinib,\                                                                                                                                                                                                0.5 ng/mL\      
  Trametinib\                                                                                                                                                                                                  0.5 ng/mL\      
  Binimetinib                                                                                                                                                                                                  0.75 ng/mL      

  Thalidomide\                    Anticancer drug                                                  h-serum     SPE    C18 (50 × 2.1 mm, 2.5 μm)        GRA      ESI(+)    AN    89--100\            5.0        4 ng/mL\        \[[@B61-pharmaceutics-10-00221]\]
  Lenalidomide\                                                                                                                                                                 60--64\                        2 ng/mL\        
  Cyclophosphamide\                                                                                                                                                             113--124\                      2 ng/mL\        
  Bortezomib\                                                                                                                                                                   103--126\                      2 ng/mL\        
  Dexamethasone\                                                                                                                                                                90--92\                        2 ng/mL\        
  Adriamycin                                                                                                                                                                    143--163\                      2 ng/mL         

  MG\                             Natural compounds                                                r-blood     LLE    C18 (50 × 2.1 mm, 5 µm) UPLC     GRA      ESI(+)    AN    76--87\             5.0        19.5 nmol/L\    \[[@B62-pharmaceutics-10-00221]\]
  PGG                                                                                                                                                                           80--104                        39 nmol/L       

  Allitinib\                      Irreversible inhibitor of the EGFR 1/2                           h-plasma    PPT    C18 (50 × 4.6 mm, 1.8 µm)        GRA      ESI(+)    AN    98.7--105.0         5.0        0.3 ng/mL\      \[[@B63-pharmaceutics-10-00221]\]
  M6\                                                                                                                                                                                                          0.03 ng/mL\     
  M10                                                                                                                                                                                                          0.075 ng/mL     

  Gefitinib\                      EGFR tyrosine kinase inhibitors                                  h-plasma    LLE    C18 (50 × 2.1 mm, 3.5 µm) UPLC   ISO      ESI(+)    AN    UNK                 5.0        0.01 nmol/L\    \[[@B64-pharmaceutics-10-00221]\]
  Erlotinib\                                                                                                                                                                                                   0.01 nmol/L\    
  Afatinib                                                                                                                                                                                                     0.05 nmol/L     

  CP\                             Anticancer drug                                                  h-plasma    PPT    C18 (150 × 2.1 mm, 5 μm)         GRA      ESI(+)    IL\   UNK                 6.0        0.2 µg/mL\      \[[@B65-pharmaceutics-10-00221]\]
  4OHCP                                                                                                                                                                   AN                                   0.05 µg/mL      

  Clofarabine\                    Anticancer drug                                                  h-plasma    PPT    C18 (150 × 2.0 mm, 4 μm)         GRA      ESI(+)    AN    None                6.0        8 ng/mL\        \[[@B66-pharmaceutics-10-00221]\]
  Cytarabine                                                                                                                                                                                                   20 ng/mL        

  Gefitinib\                      EGFR tyrosine kinase inhibitor & its metabolites                 m-plasma    PPT    C18 (50 × 2.1 mm, 1.8 m)         GRA      ESI(+)    AN    86--112             6.0        1 ng/mL\        \[[@B67-pharmaceutics-10-00221]\]
  M523595\                                                                                                                                                                                                     1 ng/mL\        
  M537194\                                                                                                                                                                                                     1 ng/mL\        
  M387783\                                                                                                                                                                                                     1 ng/mL\        
  M608236                                                                                                                                                                                                      1 ng/mL\        
                                                                                                                                                                                                               0.5 ng/mL       

  Exemestane\                     Steroidal aromatase inhibitor                                    h-plasma    PPT    C18 (100 × 2.1 mm, 5 µm)         GRA      ESI(+)    AN    62.2\               6.0        0.4 ng/mL\      \[[@B68-pharmaceutics-10-00221]\]
  17β-2H-EXE\                                                                                                                                                                   54.2\                          0.2 ng/mL\      
  17β-2H-EXE-Glu                                                                                                                                                                33.8                           0.2 ng/mL       

  CPT-11\                         Topoisomerase I inhibitor                                        h-plasma    PPT    C18 (50 × 2.0 mm, 2.6 µm)        GRA      ESI(+)    AN    91.0                6.0        0.5 ng/mL\      \[[@B69-pharmaceutics-10-00221]\]
  SN-38\                                                                                                                                                                                                       0.2 ng/mL\      
  SN-38G\                                                                                                                                                                                                      0.5 ng/mL\      
  APC\                                                                                                                                                                                                         0.5 ng/mL\      
  NPC                                                                                                                                                                                                          0.2 ng/mL       

  Sinotecan\                      Anticancer agent                                                 h-blood     PPT    C8 (150 × 4.6 mm, 5 µm)          GRA      ESI(+)    AN    104--114            6.0        1 ng/mL\        \[[@B70-pharmaceutics-10-00221]\]
  7-HEC                                                                                                                                                                                                        0.5 ng/mL       

  Letrozole\                      Aromatase inhibitor and its metabolites                          h-pls       SPE    C18 (50 × 4.6 mm, 1.8 μm) UPLC   GRA      \         \     30--31\             6.0        20 nmol/L\      \[[@B71-pharmaceutics-10-00221]\]
  Carbinol\                                                                                                                                                     \         \     \                              0.2 nmol/L\     
  carbinol glucuronide                                                                                                                                          ESI(+)    IL    90--100                        2 nmol/L        

  PR104\                          Hypoxia-activated prodrug                                        h-plasma    PPT    C18 (50 × 2.1 mm, 1.8 µm) UPLC   GRA      ESI(+)    IL    87.4--112.6         6.0        0.1 µmol/L\     \[[@B72-pharmaceutics-10-00221]\]
  PR-104A\                                                                                                                                                                                                     0.05 µmol/L\    
  PR-104G\                                                                                                                                                                                                     0.05 µmol/L\    
  PR-104H\                                                                                                                                                                                                     0.025 µmol/L\   
  PR-104M                                                                                                                                                                                                      0.01 µmol/L     

  CA4P\                           Antitumor vascular disrupting agent                              d-plasma    PPT    C18 (150 × 3.0 mm, 5 μm)         GRA      ESI(+)\   AN    NEG                 6.0        5 ng/mL         \[[@B73-pharmaceutics-10-00221]\]
  CA4\                                                                                                                                                          ESI(+)\                                                        
  CA4-Glu                                                                                                                                                       ESI(−)                                                         

  Paclitaxel\                     Regulators of microtubule formation                              h-plasma    LLE    C18 (100 × 2.1 mm, 3.5 µm)       ISO      ESI(+)    AN    86.7--102.5         6.0        25 ng/mL\       \[[@B74-pharmaceutics-10-00221]\]
  Docetaxel\                                                                                                                                                                                                   10 ng/mL\       
  Vinblastine\                                                                                                                                                                                                 10 ng/mL\       
  Vinorelbine                                                                                                                                                                                                  10 ng/mL        

  17AAG\                          HSP90 inhibitor                                                  h-plasma    PPT    C18 (50 × 2.1 mm, 5 μm)          GRA      ESI(+)    AN    UNK                 7.0        0.5 ng/mL\      \[[@B75-pharmaceutics-10-00221]\]
  17AG                                                                                                                                                                                                         0.5 ng/mL       
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: Prep: sample preparation; S-Ph (M-Ph): Solid phase (Mobile phase); E-mode: Elution mode; Interf: Interface; IS: Internal standard; RT: Run time; LLOQ: Lower limit of quantitation; Ref.: Reference number; h: human; m: mouse; r: rat; d: dog; LLE: liquid-liquid extraction; SPE: solid phase extraction; PPT: protein precipitation; ISO: isocratic elution; GRA: gradient elution; AN: analogue internal standard; IL: isotope labeled internal standard; CP: Cyclophosphamide; 4OHCP: 4-hydroxycyclophosphamide; O-DMG:O-desmethyl gefitinib; MTX: Methotrexate; L-DOX: Liposomal doxorubicin; LBH589: Panobinostat; MG: methyl gallate; PGG: pentagalloyl glucopyranose; 17β-2H-EXE: 17β-hydroxyexemestane; 17β-2H-EXE-Glu: 17β-hydroxyexemestane-17-O-β-D-glucuronide A; 7-HEC: 7-hydroxyethyl-camptothecin; PR104: (A: alcohol; H: hydroxylamine; M: amine; G: O-glucuronide); CA4P: combretastatin A4 phosphate; CA4: combretastatin A4; CA4G: combretastatin A4 glucuronide; 17AAG: 17-(allylamino)-17-demethoxygeldanamycin; 17AG: 17-amino-17-demethoxygeldanamycin; NEG: negligible matrix effect; SIG: significant matrix effect; UNK: unknown.

[^1]: Equal contribution.
